Antiretroviral Agents in HIV-1

Antiretroviral Agents in HIV

DHHS HIV GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/65244

Contents of this Issue

Navigation

Page 19 of 25

Selecting a Treatment Regimen Table 5C. Characteristics of Protease Inhibitors (PIs) Drug Formulation Tipranavir (TPV) Aptivus® 250 mg capsules or 100 mg/mL oral solution Dosing Recommendations (TPV 500 mg + RTV 200 mg) orally bid ▶ Unboosted TPV is NOT recommended ▶ TPV taken with RTV tablets: Take with meals ▶ TPV taken with RTV capsules or solution: Take without regard to meals Table 5D. Characteristics of Integrase Strand Transfer Inhibitors (INSTI) Drug Raltegravir (RAL) Isentress® Formulation 400 mg tablets Dosing Recommendations Chewable tablets 100 mg scored and 25 mg Adults: 400 mg bid Children and Adolescents: ≥ 12 years: 400 mg bid 6 - 11 years: ≥ 25 kg: one 400 mg bid or Chewable tablets: weight based– (see PI) Max: 300 mg bid 2 -<6 years: If ≥ 10 kg: Chewable tablets: weight based– Max: 300 mg bid < 25 kg: Chewable tablets: weight based– Max: 300 mg bid With rifampin: 800 mg bid ▶ Take without regard to meals 18

Articles in this issue

Archives of this issue

view archives of Antiretroviral Agents in HIV-1 - Antiretroviral Agents in HIV